Linked Life Data

9094686

Source:http://linkedlifedata.com/resource/pubmed/id/9094686

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
1997-4-25
pubmed:abstractText
We have approached the development of a human immunodeficiency virus type 1 (HIV-1) therapeutic product by producing immune cells stably resistant to HIV-1. Promonocytic CD4+ cells (U937) were made resistant to HIV-1 by the introduction of a DNA construct (pNDU1A,B,C) that contained three independent antisense sequences directed against two functional regions, transactivation response and tat/rev, of the HIV-1 target. Each sequence was incorporated into the transcribed region of a U1 snRNA gene to generate U1/HIV antisense RNA. Stably transfected cells expressed all three U1/HIV antisense transcripts, and these transcripts accumulated in the nucleus. These cells were subjected to two successive challenges with HIV-1 (BAL strain). The surviving cells showed normal growth characteristics and have retained their CD4+ phenotype. In situ hybridization assays showed that essentially all of the surviving cells produced U1/HIV antisense RNA. No detectable p24 antigen was observed, no syncytium formation was observed, and PCR-amplified HIV gag sequences were not detected. Rechallenge with HIV-1 (IIIB strain) similarly yielded no infection at a relatively high multiplicity of infection. As a further demonstration that the antisense RNA directed against HIV-1 was functioning in these transfected immune cells, Tat-activated expression of chloramphenicol acetyltransferase was shown to be specifically inhibited in cells expressing Tat and transactivation response region antisense sequences.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/9094686-1359646, http://linkedlifedata.com/resource/pubmed/commentcorrection/9094686-1501292, http://linkedlifedata.com/resource/pubmed/commentcorrection/9094686-1569345, http://linkedlifedata.com/resource/pubmed/commentcorrection/9094686-1702158, http://linkedlifedata.com/resource/pubmed/commentcorrection/9094686-1945853, http://linkedlifedata.com/resource/pubmed/commentcorrection/9094686-1985211, http://linkedlifedata.com/resource/pubmed/commentcorrection/9094686-2015571, http://linkedlifedata.com/resource/pubmed/commentcorrection/9094686-2138975, http://linkedlifedata.com/resource/pubmed/commentcorrection/9094686-2297571, http://linkedlifedata.com/resource/pubmed/commentcorrection/9094686-2990040, http://linkedlifedata.com/resource/pubmed/commentcorrection/9094686-3001360, http://linkedlifedata.com/resource/pubmed/commentcorrection/9094686-5388124, http://linkedlifedata.com/resource/pubmed/commentcorrection/9094686-6179629, http://linkedlifedata.com/resource/pubmed/commentcorrection/9094686-7849487, http://linkedlifedata.com/resource/pubmed/commentcorrection/9094686-7914231, http://linkedlifedata.com/resource/pubmed/commentcorrection/9094686-7981305, http://linkedlifedata.com/resource/pubmed/commentcorrection/9094686-8043518, http://linkedlifedata.com/resource/pubmed/commentcorrection/9094686-8377194
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
0022-538X
pubmed:author
pubmed:issnType
Print
pubmed:volume
71
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
4079-85
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
1997
pubmed:articleTitle
Stable human immunodeficiency virus type 1 (HIV-1) resistance in transformed CD4+ monocytic cells treated with multitargeting HIV-1 antisense sequences incorporated into U1 snRNA.
pubmed:affiliation
Enzo Biochem, Inc., Farmingdale, New York 11735, USA. dl@enzobio.com
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't